Yahoo
    NasdaqGM - Nasdaq Real Time Price USD

    ARS Pharmaceuticals, Inc. (SPRY)

    3.3800 -0.2800 (-7.65%)
    At close: October 30 at 4:00:00 PM EDT
    3.3800 0.0000 (0.00%)
    After hours: October 30 at 4:27:10 PM EDT
    Trade SPRY on Coinbase
    Chart Range Bar
    Advanced Chart
    AlphaSpace Chart
    Loading chart for SPRY
    • Previous Close 3.6600
    • Open 3.6200
    • Bid 3.8900 x 200
    • Ask 6.7200 x 200
    • Day's Range 3.3450 - 3.7900
    • 52 Week Range 3.3400 - 13.1500
    • Volume 1,754,250
    • Avg. Volume 1,657,558
    • Market Cap (intraday) 336.132M
    • Beta (5Y Monthly) 1.08
    • PE Ratio (TTM) --
    • EPS (TTM) -2.1800
    • Earnings Date Nov 5, 2026
    • Forward Dividend & Yield -- (0.00%)
    • 1y Target Est 24.33
    • Zacks Rating Bearish

    ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

    ars-pharma.com

    195

    Full Time Employees

    December 31

    Fiscal Year Ends

    Healthcare

    Sector

    Biotechnology

    Industry

    More about ARS Pharmaceuticals, Inc.

    Recent News

    View More
    View More

    Performance Overview

    Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

    YTD Return

    SPRY
    70.99%
    S&P 500 (^GSPC)
    10.73%

    1-Year Return

    SPRY
    60.79%
    S&P 500 (^GSPC)
    11.11%

    3-Year Return

    SPRY
    2.87%
    S&P 500 (^GSPC)
    81.91%

    5-Year Return

    SPRY
    60.83%
    S&P 500 (^GSPC)
    64.59%

    Earnings Trends

    View More

    Earnings Per Share

    GAAP
    Normalized
    GAAP
    Normalized

    Revenue vs. Earnings

    Annual
    Quarterly
    Annual
    Quarterly
    Q2 FY26
    Revenue 33.66M
    Earnings -62.34M
    Profit Margin -185.21%

    Q3

    FY25

    Q4

    FY25

    Q1

    FY26

    Q2

    FY26

    -60M
    -40M
    -20M
    0
    20M
    -260.0%
    -240.0%
    -220.0%
    -200.0%
    -180.0%
    -160.0%
    View More

    Analyst Insights

    View More

    Analyst Price Targets

    15.00
    24.33 Average
    3.3800 Current
    30.00 High

    Analyst Recommendations

    • Strong Buy
    • Buy
    • Hold
    • Underperform
    • Sell

    Latest Rating

    Date 8/13/2026
    Analyst Leerink Partners
    Rating Action Maintains
    Rating Outperform
    Price Action Lowers
    Price Target 24 -> 18
    View More

    Statistics

    View More

    Valuation Measures

    Annual

    • Market Cap

    • Enterprise Value

    • Trailing P/E

    • Forward P/E

    • PEG Ratio (current)

    • Price/Sales (ttm)

    • Price/Book (mrq)

    • Enterprise Value/Revenue

    • Enterprise Value/EBITDA

    Financial Highlights

    Profitability and Income Statement

    • Profit Margin

      -184.24%

    • Return on Assets (ttm)

      -48.02%

    • Return on Equity (ttm)

      -210.35%

    • Revenue (ttm)

      116.93M

    • Net Income Avi to Common (ttm)

      -215.43M

    • Diluted EPS (ttm)

      -2.1800

    Balance Sheet and Cash Flow

    • Total Cash (mrq)

      143.84M

    • Total Debt/Equity (mrq)

      1,371.51%

    • Levered Free Cash Flow (ttm)

      -117.7M

    View More

    Company Insights

    Research Reports

    View More
    View More

    People Also Watch

    EWTX Edgewise Therapeutics, Inc.
    38.90 -0.03%
    PHAT Phathom Pharmaceuticals, Inc.
    5.74 -7.72%
    TVTX Travere Therapeutics, Inc.
    50.39 -0.36%
    TARS Tarsus Pharmaceuticals, Inc.
    74.85 +0.88%
    TNGX Tango Therapeutics, Inc.
    22.72 +0.84%
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: